B A Parker - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Cell Cycle (Georgetown, Tex.)|May 8, 2015

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsA Parish, M Schwaederle, G Daniels, et al.

Blood|May 1, 1996

Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodiesC A White, S E Halpern, B A Parker, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993

AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B studyB A Parker, M Santarelli, M R Green, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000

Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.

Cancer Research|February 1, 1990

Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibodyB A Parker, A B Vassos, S E Halpern, et al.

Cancer|July 24, 2001

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854N L Bartlett, G R Petroni, B A Parker, et al.

Clinical Pharmacology and Therapeutics|March 25, 2011

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesL Madlensky, L Natarajan, S Tchu, et al.

Breast Cancer Research and Treatment|December 23, 2016

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcomeA H M de Vries Schultink, X Alexi, E van Werkhoven, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Cell Cycle (Georgetown, Tex.)|May 8, 2015

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsA Parish, M Schwaederle, G Daniels, et al.

Blood|May 1, 1996

Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodiesC A White, S E Halpern, B A Parker, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993

AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B studyB A Parker, M Santarelli, M R Green, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000

Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.

Cancer Research|February 1, 1990

Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibodyB A Parker, A B Vassos, S E Halpern, et al.

Cancer|July 24, 2001

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854N L Bartlett, G R Petroni, B A Parker, et al.

Clinical Pharmacology and Therapeutics|March 25, 2011

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesL Madlensky, L Natarajan, S Tchu, et al.

Breast Cancer Research and Treatment|December 23, 2016

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcomeA H M de Vries Schultink, X Alexi, E van Werkhoven, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.

Pageof 2